spacer
home > ebr > summer 2007 > air fermentation: risks and benefits
PUBLICATIONS
European Biopharmaceutical Review

Air Fermentation: Risks and Benefits

Monica Cardona at Pall Life Sciences investigates techniques for increasing yield in mammalian and microbial cell culture applications using enriched and pure gaseous oxygen

Many valuable biopharmaceutical and biotechnological products are produced by aerobic fermentation, which includes mammalian and microbial cell culture applications. Worldwide demand for fermentation products has been increasing steadily, and this trend is expected to continue. To improve productivity, manufacturers are trying to run high-strength broths with higher biomass levels to achieve larger product yields. Because of this trend, and the fact that eliminating oxygen starvation phases can increase bioreactor and fermenter yields, improved aeration concepts have recently been established to satisfy the additional oxygen demands of fermentation and cell culture unit operations.

Modern aeration increasingly uses enriched or pure gaseous oxygen to improve cell culture productivity. Sterilising grade gas filters that can be integrity-tested by means of a water intrusion test (WIT) are the best way to prevent spoilage of bioreactors and fermenters by organisms and contaminants in incoming and outgoing air and oxygen streams.

However, many materials, such as organic matter, plastics or metals, can potentially ignite when they come into contact with oxygen, particularly if they are also subjected to static discharges, high temperatures, pneumatic shocks or mechanical impact. In addition to the aforementioned safety aspects, oxygen or enriched oxygen gases can lead to accelerated oxidation or corrosion of component materials.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Monica Cardona has been with Pall Corporation since 1996. She worked as a Laboratory Analyst and as a Senior Laboratory Analyst in the microbiology laboratory. She then joined the validation group as a Validation Project Manager for compatibility and extractables projects. Today, Monica is a Marketing Manager with responsibility in the western hemisphere for direct flow filtration. She holds a BA in Biology from Hofstra University and an MA in Biology from Adelphi University.
spacer
Monica Cardona
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ERT Acquires APDM Wearable Technologies to Reinvent Endpoint Measurement in Clinical Trials

ERT, the global leader in clinical endpoints data collection, today announced the acquisition of APDM Wearable Technologies (APDM, Inc.), a next-generation provider of wearables and digital biomarkers. The combined company will generate higher-fidelity and more powerful data to enable clinical trials to be more predictable, cost-effective, and efficient. Thereby, reinventing endpoint measurement.
More info >>

White Papers
 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement